| 000 | 00907 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518065922.0 | ||
| 264 | 0 | _c20200804 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1099-1557 | ||
| 024 | 7 |
_a10.1002/pds.4899 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDutcher, Sarah K | |
| 245 | 0 | 0 |
_aUsing real-world data to evaluate biosimilar switching. _h[electronic resource] |
| 260 |
_bPharmacoepidemiology and drug safety _c07 2020 |
||
| 300 |
_a814-816 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aBiosimilar Pharmaceuticals |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aInfliximab |
| 700 | 1 | _aEworuke, Efe | |
| 700 | 1 | _aBlum, Michael D | |
| 700 | 1 | _aBall, Robert | |
| 773 | 0 |
_tPharmacoepidemiology and drug safety _gvol. 29 _gno. 7 _gp. 814-816 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pds.4899 _zAvailable from publisher's website |
| 999 |
_c30278705 _d30278705 |
||